Phase 2Not yet recruitingAge-related condition
A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients
A Phase 2a, Randomized, Double-masked, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in Patients With Diabetic Macular Edema
- Sponsor
- SciNeuro (Industry)
- Enrollment
- 60 planned
- Conditions
- Diabetic Macular Edema; DME
- Interventions
- SNP318; Placebo
- Ages
- adults, older adults
- Registry
- NCT07199777
Full record on ClinicalTrials.gov
From the registry
The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.
Primary outcomes
- Safety Events
- Central Subfield Thickness (CST)
History
Study completion expected
Primary completion
Started
Registered